Disappointing Trials Results For Sativex, UK
May 15th 2008Drug InformationMultiple Sclerosis
GW Pharmaceuticals, which makes Sativex - an oral spray containing a cannabis extract - has released disappointing results of a trial testing the drug’s benefits in treating pain in people with multiple sclerosis (MS). The study involved 339 people experiencing neuropathic pain due to MS who have achieved inadequate pain relief with existing therapies.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
